Clinical Trials Browser

Interventional × Lymphoma × Antigens, CD19 × Clear all

NCT05651100 2022-12-14

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Phase 1/2 Unknown

Lymphoma, Lymphoma, B-Cell

NCT02846584 2016-09-07

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Phase 2 Unknown

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse